Navigation Links
Mayo Clinic: Raoul Tibes, M.D., Ph.D., to receive Career Development Award
Date:6/3/2011

CHICAGO -- Rauol Tibes, M.D., Ph.D., the associate director of the Acute and Chronic Leukemias Program at Mayo Clinic in Arizona, will receive a Career Development Award from the Conquer Cancer Foundation of the American Society of Clinical Oncology (formerly known as the ASCO Cancer Foundation) at the annual ASCO meeting this weekend in Chicago.

VIDEO ALERT: Additional audio and video resources are available at the Mayo Clinic News Blog.

Dr. Tibes is one of only eight researchers in the United States selected to receive the Conquer Cancer Foundation of ASCO Career Development Award this year. The award, a three year grant totaling $200,000, will help fund the next phase of Mayo Clinic's translational research in acute myeloid leukemia (AML) led by Dr. Tibes and his team of colleagues.

The Career Development Awards are presented to physicians who are within their first to third year of full-time, primary faculty appointment in a clinical department at an academic medical institution.

"I am very happy and proud," said Dr. Tibes, upon learning that his research effort from his laboratory, designed to advance new therapies for patients with acute leukemias, was recognized with this honor.

The crux of this translational research focuses on how to make the drug Cytarabine (one of the most actively used drugs administered to leukemia patients), more potent and effective, particularly for leukemia patients who have failed prior therapies and whose leukemia has relapsed.

Dr. Tibes said this kind of translational research project was greatly accelerated when he and his team began adapting RNA interference (RNAi) to leukemia research.

"We performed a large scale RNAi screening knock
'/>"/>

Contact: Julie Janovsky-Mason
newsbureau@mayo.edu
480-301-4222
Mayo Clinic
Source:Eurekalert

Page: 1 2

Related medicine news :

1. Atlanta School of Massage Celebrates 30th Anniversary with a New Green Design and New Name for its Teaching Clinic: SensAbility
2. AMA Honors Vice Admiral John Mateczun, M.D., With Top Government Service Award
3. Nationally Known Interventional Neuroradiologist John Pile-Spellman, M.D., Joins Neurological Surgery, P.C.
4. University of Utah afib specialist, Marcos Daccarett, M.D., wins Young Investigator Award
5. Joan Miller, M.D., receives 2010 Leadership Award for the Advancement of Women Faculty
6. Gino Tutera, M.D., F.A.C.O.G. Brings SottoPelle Therapy to Middle Tennessee, Opens Practice in Nashville Medical District
7. Renowned Psychiatrist, Lyubov Y Gorelik, M.D., is selected to represent New York in The Leading Physicians of the World
8. Anthony S. Fauci, M.D., on results from the CAPRISA 004 microbicide study
9. O. Marion Burton, M.D., F.A.A.P., addresses American Academy of Pediatrics in new term as president
10. Douglas A. Jabs, M.D., honored with Jackson Memorial Lecture by the American Academy of Ophthalmology
11. Donald M. Lloyd-Jones, M.D., recipient of the American Heart Associations 2010 Chairmans Award
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/20/2014)... no secret that millions of Americans are struggling with ... Abuse, nearly 24 million Americans are using some form ... fact that the total number of users has increased ... struggle with substance abuse often feel there may never ... has released updated lists of substance abuse resources ...
(Date:8/20/2014)... 2014 A Missouri federal judge has remanded ... were treated with GranuFlo and NaturaLyte to the City of ... Baron and Budd. The judge rejected an assertion by the ... were invalid. (McGee, et al. v. Fresenius Medical Care North ... Medical Care, is the manufacturer of the dialysis products GranuFlo ...
(Date:8/20/2014)... -- Taking the widely used antibiotic clarithromycin ... causes, a new study suggests. Because millions of ... urgent confirmation, said the Danish researchers behind the study. ... and that guidelines for the use of the drug ... One heart expert wasn,t surprised by the finding, ...
(Date:8/20/2014)... Chemically extracted acellular allogeneic nerve, from which ... have been removed, reduced postoperative immune rejection. ... neural substrates and base materials, such as ... can provide a good scaffold in the ... allogeneic nerve, similar to autologous nerve transplantation, ...
(Date:8/20/2014)... Angeles, CA (PRWEB) August 20, 2014 If ... has found a cure for it. With extensive research on ... provider named ‘MetroMD’ claims to have perfected the art of ... you a brand new younger look with their revolutionary anti-aging ... secrets of the 21st century fountain of youth, the MD ...
Breaking Medicine News(10 mins):Health News:Re-Launched AbuseTreatmentCenters.net Offering New List of Substance Abuse Resources 2Health News:GranuFlo/NaturaLyte Case Remanded to State Court By Missouri Federal Judge, Baron and Budd Reports 2Health News:Antibiotic Might Raise Heart Risks for Some 2Health News:MetroMD Offers Revolutionary Anti-aging Hormone Therapy in Hollywood Area 2
... may indicate underlying disease, study finds , , FRIDAY, Aug. 8 ... play a pivotal role in increasing an older American,s risk ... a new report says. , Levels of adiponectin increase in ... the cardiovascular health of older people, according to the new ...
... Alaska The University of Alaska Fairbanks campus will be ... 12-14, 2008. , The biennial conference is organized in ... Arctic Region and brings together international participants to address ... host to the 2008 conference. , More than150 guests ...
... Delivers Cheer, Medication and Equipment to Young Patients and Helps ... Raise Money for Make-A-Wish ... general,availability of its train-themed "JR" autonomous mobile robot to children,s,hospitals ... the,national Make-A-Wish Foundation for each JR TUG that is deployed. ...
... 1-inch cut behind uterus and into woman,s body cavity ... they say may be the first operation of its ... Hospital/Columbia University Medical Center removed a woman,s gallbladder without ... as part of an ongoing clinical research trial, involved ...
... EDT, Thursday, ... August 14, PRINCETON, ... advanced wound care products,announced plans to release its second quarter 2008 results ... the Company will,hold a conference call that same day to discuss the ...
... Inc. (NYSE: HGR ) is pleased to ... Hanger Orthopedic Group, Inc. to "positive",from "stable." Moody,s ... "We are pleased with the outlook change ... the last ten quarters," remarked George McHenry,Hanger,s Chief ...
Cached Medicine News:Health News:Fat Cell Protein Boosts Heart Attack Risk in Elderly 2Health News:UAF to host Eighth Conference of Arctic Parliamentarians 2Health News:Charlotte Children's Hospital Gets a Delivery from Aethon's Train-Themed Robot This Fall 2Health News:Charlotte Children's Hospital Gets a Delivery from Aethon's Train-Themed Robot This Fall 3Health News:New Technique Removes Gallbladder Without External Incisions 2Health News:Derma Sciences Conference Call Advisory 2
(Date:8/20/2014)... , Aug. 20, 2014  Glades Drugs, an independent ... is proud to announce its expansion into a new corporate ... will feature an 8,000-square-foot office space and state of the ... applications for 100 open positions for the new facility. ... Lantana Road will serve as the chain,s corporate headquarters and ...
(Date:8/20/2014)... Reportlinker.com announces that a new market research report ... Patient Scales Industry http://www.reportlinker.com/p01374301/Global-Patient-Scales-Industry.html ... markets for Patient Scales in US$ Thousand by ... Baby Scales, Chair Scales, and Under Bed Scales. ... US, Canada, Japan, Europe, Asia-Pacific, Latin America, and ...
(Date:8/20/2014)... 2014 Phase I Trial of ... KalVista Pharmaceuticals ("KalVista"), an ophthalmology company with ... that it has begun a Phase I, First in ... for the treatment of DME. The study,s Principal Investigator ... Institute, Joslin Diabetes Center; Harvard Medical School Department of ...
Breaking Medicine Technology:Glades Drugs Moves to New Corporate Headquarters, 100 Open Positions 2Global Patient Scales Industry 2Global Patient Scales Industry 3Global Patient Scales Industry 4Global Patient Scales Industry 5Global Patient Scales Industry 6Global Patient Scales Industry 7Global Patient Scales Industry 8Global Patient Scales Industry 9Global Patient Scales Industry 10Global Patient Scales Industry 11Global Patient Scales Industry 12Global Patient Scales Industry 13Global Patient Scales Industry 14Global Patient Scales Industry 15Global Patient Scales Industry 16Global Patient Scales Industry 17Global Patient Scales Industry 18Global Patient Scales Industry 19KalVista Pharmaceuticals Announces Start of Clinical Development for Novel Treatment for Diabetic Macular Edema 2KalVista Pharmaceuticals Announces Start of Clinical Development for Novel Treatment for Diabetic Macular Edema 3KalVista Pharmaceuticals Announces Start of Clinical Development for Novel Treatment for Diabetic Macular Edema 4
... - Biovest,International, Inc. (OTCBB: BVTI), a majority owned ... 2007 blinded interim data from the start of ... for Non-Hodgkin's,lymphoma (NHL) from September 2000 through June ... data that has been made available,to the Company ...
... at the 11th International Myeloma Workshop -, NORTH ... -- The International Myeloma Foundation (IMF) --,supporting research ... families, researchers and physicians -- today,said that updated ... Greece demonstrate improved survival for a wide,range of ...
Cached Medicine Technology:Based on Up to 6 Years of Follow-Up, Biovest Announces Favorable,Interim Blinded Data for Fast-Tracked Pivotal Phase 3 Clinical,Trial of BiovaxID Anti-Cancer Vaccine for Non-Hodgkin's Lymphoma 2Based on Up to 6 Years of Follow-Up, Biovest Announces Favorable,Interim Blinded Data for Fast-Tracked Pivotal Phase 3 Clinical,Trial of BiovaxID Anti-Cancer Vaccine for Non-Hodgkin's Lymphoma 3Based on Up to 6 Years of Follow-Up, Biovest Announces Favorable,Interim Blinded Data for Fast-Tracked Pivotal Phase 3 Clinical,Trial of BiovaxID Anti-Cancer Vaccine for Non-Hodgkin's Lymphoma 4Based on Up to 6 Years of Follow-Up, Biovest Announces Favorable,Interim Blinded Data for Fast-Tracked Pivotal Phase 3 Clinical,Trial of BiovaxID Anti-Cancer Vaccine for Non-Hodgkin's Lymphoma 5The International Myeloma Foundation Says Data Reported at a Global,Medical Meeting in Greece Demonstrates Improved Survival for a Wide,Range of Myeloma Patients 2The International Myeloma Foundation Says Data Reported at a Global,Medical Meeting in Greece Demonstrates Improved Survival for a Wide,Range of Myeloma Patients 3The International Myeloma Foundation Says Data Reported at a Global,Medical Meeting in Greece Demonstrates Improved Survival for a Wide,Range of Myeloma Patients 4
The Calcitonin ELISA is intended for the quantitative determination of Calcitonin in human serum....
... wavelength (532 nm and 940 nm) laser ... solution. This solid-state laser quickly and effectively ... vulgaris. VariLite offers the clinical versatility to ... deeper, larger vessels in a convenient, affordable ...
... PREMIUM SURGICLIP™ clip applier consists of an applier ... 15 or 20 titanium clips. , ,The ... or other tubular structure. As the handles of ... closed around the vessel or structure. As the ...
The LIGACLIP ERCA Endoscopic Rotating Multiple Clip Applier is intended for use on tubular structures or vessels wherever a metal ligating clip is indicated. The tissue being ligated should be consis...
Medicine Products: